Highlights in psoriatic arthritis from ACR 2024 include results of methotrexate added to DMARD therapy, responses to bimekizumab, and improvements gained by upadacitinib after prior TNF inhibitor use.
Request To Download Free Sample of This Strategic Report @- In addition, rise in patient awareness toward availability of various treatments for rheumatoid arthritis, increase in focus of ...